IM73 CAR-T cells
/ Beijing Imunopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 23, 2021
Donor-derived CAR-T Cells in the Treatment of AML Patients
(clinicaltrials.gov)
- P1; N=9; Not yet recruiting; Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
Clinical • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
1 to 1
Of
1
Go to page
1